Cancer mortality was also significantly lower among patients assigned to receive canakinumab than among those in the placebo group, a finding that is consistent with experimental data relating IL-1 to the progression and invasiveness of certain tumors, particularly lung cancer. This evidence concerns the gene IL1A and lung carcinoma.